Search Results

You are looking at 1 - 3 of 3 items for

  • Author: AB Grossman x
  • Refine by access: All content x
Clear All Modify Search
A.B. Grossman
Search for other papers by A.B. Grossman in
Google Scholar
PubMed
Close
,
W.G. Rossmanith
Search for other papers by W.G. Rossmanith in
Google Scholar
PubMed
Close
,
E.B. Kabigting
Search for other papers by E.B. Kabigting in
Google Scholar
PubMed
Close
,
G. Cadd
Search for other papers by G. Cadd in
Google Scholar
PubMed
Close
,
D. Clifton
Search for other papers by D. Clifton in
Google Scholar
PubMed
Close
, and
R.A. Steiner
Search for other papers by R.A. Steiner in
Google Scholar
PubMed
Close

ABSTRACT

Using probes for rat neural nitric oxide synthase (NOS) mRNA and GnRH mRNA, we performed in situ hybridization to survey NOS mRNA distribution within the hypothalamus of the male and female rat and sought evidence for its expression in GnRH neurons. The NOS cRNA probe was radiolabelled with 35S, and a digoxigenin-labeled rat GnRH cRNA probe was used for double-label studies. NOS mRNA was localized in discrete hypothalamic areas, in grain clusters suggestive of individual neurons. NOS mRNA-positive cells were located mainly in the supraoptic and paraventricular nucleus, particularly overlying the magnocellular division. Rostrally, cells expressing NOS mRNA were especially prominent in the diagonal band of Broca, in a distribution very similar to GnRH neurons. Nevertheless, only one of 370 cells labeled for GnRH mRNA appeared to be positive for NOS mRNA. We conclude that NOS mRNA is located prominently in regions where CRH, AVP and oxytocin cells are located. NOS mRNA-positive cells are located in close proximity to GnRH neurons, but rarely do such neurons express NOS mRNA.

Restricted access
VV Vax
Search for other papers by VV Vax in
Google Scholar
PubMed
Close
,
R Bibi
Search for other papers by R Bibi in
Google Scholar
PubMed
Close
,
S Diaz-Cano
Search for other papers by S Diaz-Cano in
Google Scholar
PubMed
Close
,
M Gueorguiev
Search for other papers by M Gueorguiev in
Google Scholar
PubMed
Close
,
B Kola
Search for other papers by B Kola in
Google Scholar
PubMed
Close
,
N Borboli
Search for other papers by N Borboli in
Google Scholar
PubMed
Close
,
B Bressac-de Paillerets
Search for other papers by B Bressac-de Paillerets in
Google Scholar
PubMed
Close
,
GJ Walker
Search for other papers by GJ Walker in
Google Scholar
PubMed
Close
,
Dedov II
Search for other papers by Dedov II in
Google Scholar
PubMed
Close
,
AB Grossman
Search for other papers by AB Grossman in
Google Scholar
PubMed
Close
, and
M Korbonits
Search for other papers by M Korbonits in
Google Scholar
PubMed
Close

Cell cycle dysregulation is one of the defining features of cancer. Cyclin-dependent kinase 4 (CDK4), together with its regulatory subunit cyclin D, governs cell cycle progression through the G1 phase. Cyclin-dependent kinase inhibitors, including p16(INK4A) (encoded by CDKN2A), in turn regulate CDK4. In particular, dysregulation of the p16/CDK4/cyclin D complex has been established in a variety of types of human tumours. Dominant activating mutations affecting codon 24 of the CDK4 gene (replacement of Arg24 by Cys or His) render CDK4 insensitive to p16(INK4) inhibition and are responsible for melanoma susceptibility in some kindreds. However, 'knock-in' mice homozygous for the CDK4(R24C) mutation were noted to develop multiple neoplasia, most commonly including endocrine tumours: pituitary adenomas, insulinomas and Leydig cell testicular tumours. We therefore speculated that sporadic human endocrine tumours might also harbour such mutations. The aim of the current study was to analyze the CDK4 gene for the two characterized activating mutations, R24C and R24H, in sporadic human pituitary adenomas, insulinomas and Leydig cell tumours. We used DNA extracted from 61 pituitary adenomas, and paired tumorous and neighboring normal genomic DNA extracted from 14 insulinoma and 6 Leydig cell tumour samples. Genomic DNA from patients with familial melanoma harbouring the R24C or the R24H mutations served as positive controls. All samples were subjected to PCR, mutation-specific restriction digests and/or sequencing. Both methodologies failed to detect mutations at these two sites in any of the sporadic endocrine tumours including pituitary adenomas, benign or malignant insulinomas or Leydig cell tumours, while the positive controls showed the expected heterozygote patterns. Protein expression of CDK4 was demonstrated by immunohistochemistry and Western blotting in pituitary and pancreatic samples. These data suggest that the changes in the regulatory 'hot-spot' on the CDK4 gene, causing various endocrine tumours in CDK4(R24C/R24C )mice, are not a major factor in sporadic pituitary, insulin beta-cell or Leydig cell tumorigenesis.

Free access
ME Pyle
Search for other papers by ME Pyle in
Google Scholar
PubMed
Close
,
M Korbonits
Search for other papers by M Korbonits in
Google Scholar
PubMed
Close
,
M Gueorguiev
Search for other papers by M Gueorguiev in
Google Scholar
PubMed
Close
,
S Jordan
Search for other papers by S Jordan in
Google Scholar
PubMed
Close
,
B Kola
Search for other papers by B Kola in
Google Scholar
PubMed
Close
,
DG Morris
Search for other papers by DG Morris in
Google Scholar
PubMed
Close
,
A Meinhardt
Search for other papers by A Meinhardt in
Google Scholar
PubMed
Close
,
MP Powell
Search for other papers by MP Powell in
Google Scholar
PubMed
Close
,
FX Claret
Search for other papers by FX Claret in
Google Scholar
PubMed
Close
,
Q Zhang
Search for other papers by Q Zhang in
Google Scholar
PubMed
Close
,
C Metz
Search for other papers by C Metz in
Google Scholar
PubMed
Close
,
R Bucala
Search for other papers by R Bucala in
Google Scholar
PubMed
Close
, and
AB Grossman
Search for other papers by AB Grossman in
Google Scholar
PubMed
Close

Macrophage migration inhibitory factor (MIF) is an essential regulator of the macrophage responses to endotoxin. MIF also has the ability to override the anti-inflammatory actions of glucocorticoids during an immune response, and is thus an important pro-inflammatory factor. The presence of MIF in cells of the anterior pituitary has been described, and high levels of MIF in other rapidly proliferating tIssues have also been demonstrated. It has been hypothesised that MIF release from these cells is influenced by the hypothalamo-pituitary-adrenal axis, and that ACTH and MIF are released simultaneously to exert counter-regulatory effects on cortisol. However, another intracellular role for MIF has also been suggested as it has been shown that MIF exerts an effect on the inhibitory cell cycle control protein p27 through an interaction with Jab1, a protein implicated in p27 degradation. We studied MIF expression in different normal and adenomatous human pituitary samples using immunohistochemistry and RT-PCR. There was evidence of co-immunoprecipitation of MIF with Jab1, suggesting an interaction of the two proteins. Our results showed that there is increased expression of MIF protein in the nuclei of all pituitary adenomas compared with normal tIssue (P=0.0067), but there was no statistically significant difference in nuclear MIF expression between the different adenoma types. Nuclear MIF expression correlated positively with p27 and its phosphorylated form in normal tIssue (P=0.0028 and P<0.0001); however, this relationship was not seen in the adenoma samples. Cytoplasmic expression of MIF was found to be variable both in normal and adenomatous samples, with no consistent pattern. MIF mRNA was demonstrated to be present in all tumour and normal samples studied. Somatotroph tumours showed higher MIF mRNA expression compared with normal pituitary or other types of adenomas. In conclusion, MIF is expressed in cell nuclei in pituitary adenomas to a greater extent than in normal pituitary tIssue. We speculate that it may play a role in the control of the cell cycle, but whether its higher level in adenomas is a cause or a consequence of the tumorigenic process remains to be clarified.

Free access